New drug cocktail aims to tame deadly transplant complication
NCT ID NCT07570745
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a new oral drug (ivarmacitinib) to standard medicines can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant from a female donor who has given birth. About 82 adults with blood cancers will receive the drug combo and be monitored for 6 months. The goal is to reduce severe GVHD while keeping the transplant working.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE MARROW TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital Affiliated to Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI platform aims to unlock Real-World cancer data on a massive scale
- DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
- Can a lung protein tame severe graft-versus-host disease?
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- Could a common arthritis drug shield transplant patients from a dangerous virus?
- New biologic MK-1045 targets Hard-to-Treat blood cancers